Histogen, Inc.

126 articles with Histogen, Inc.

• Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

  3/16/2023

  Histogen Inc. (NASDAQ: HSTO) today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 11,579,703 titled “Caspase Inhibitors and Methods of Use Thereof.”

• Histogen Reports Year-End 2022 Results and Provides Business Update

  3/9/2023

  Histogen Inc. reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments.

• Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 27, 2023

  2/27/2023

  Histogen Inc. announced the Board of Directors, upon the recommendation of the Company’s Compensation Committee granted Alfred J. Spada, the company’s recently appointed Executive Vice President and Chief Scientific Officer, a nonqualified stock option to purchase 106,793 shares of Histogen Inc. common stock with an exercise price of $1.04 based on the closing price on February 23, 2023, the grant date of the award.

• Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

  1/3/2023

  Histogen Inc. announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer.

• Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Histogen Inc. (NASDAQ: HSTO) today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments.

• Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Histogen Inc. (NASDAQ: HSTO), today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

  7/27/2022

  Histogen Inc. announced that Histogen’s financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022.

• Histogen Announces 1-for-20 Reverse Stock Split

  6/1/2022

  Histogen Inc., a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock.

• Histogen to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Histogen Inc. announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

• Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Histogen Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

  4/28/2022

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

• Histogen Announces Closing of $4.75 Million Private Placement

  3/25/2022

  Histogen Inc. announced the closing of its previously announced private placement for the issuance and sale of 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

• Histogen Announces $4.75 Million Private Placement

  3/23/2022

  Histogen Inc. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

• Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdatePhase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023

  3/10/2022

  Histogen Inc. reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

  3/3/2022

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.

• Histogen Announces Closing of $3.5 Million Private Placement

  12/21/2021

  Histogen Inc. announced the closing of its previously announced private placement for the issuance and sale of 8,235,297 shares of common stock and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock and associated warrant.

• Histogen Announces $3.5 Million Private Placement

  12/16/2021

  Histogen Inc. (NASDAQ: HSTO), announced today that it has entered into securities purchase agreements with certain institutional and accredited investors to issue, in a private placement, 8,235,297 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,235,297 shares of common stock.

• Histogen Reports Third Quarter 2021 Earnings and Provides Business Update

  11/10/2021

  Histogen Inc. (NASDAQ: HSTO), today reported financial results for the third quarter ended September 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen Announces CEO Transition

  11/8/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Executive Chairman and Interim President and Chief Executive Officer effective immediately.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.